
Our Pipeline
Mycovia is committed to the development of a robust pipeline of novel therapies to address the needs of patients living with overlooked medical conditions in women’s health and beyond.
Source: Mycovia Source Data on File
*VT-1598 has QIDP designation, Fast Track status, and orphan designation for Valley fever (coccidioides); cryptococcal meningitis is eligible for FDA’s priority review voucher program.

Worldwide clinical trials were completed for oteseconazole.